Viewing StudyNCT06386263

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 8:27 PM
Last Modification Date: 2024-10-26 @ 3:28 PM
Study NCT ID: NCT06386263
Status: RECRUITING
Last Update Posted: 2024-06-10
First Post: 2024-04-03
Brief Title: HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
Sponsor: AstraZeneca
Organization: AstraZeneca
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
HER2-positive Breast Cancer
Unresectable Breast Cancer
Metastatic Breast Cancer
HER2-low Expressing Breast Cancer
Keywords:
Name View
Observational View
Breast Cancer View
Metastatic breast cancer View
HER-TEMPO View
Trastuzumab Deruxtecan View
Enhertu View